0001415889-24-024867.txt : 20241008 0001415889-24-024867.hdr.sgml : 20241008 20241008161508 ACCESSION NUMBER: 0001415889-24-024867 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241004 FILED AS OF DATE: 20241008 DATE AS OF CHANGE: 20241008 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brandt Peter C. CENTRAL INDEX KEY: 0001434099 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39692 FILM NUMBER: 241360485 MAIL ADDRESS: STREET 1: NOVEN PHARMACEUTICALS, INC. STREET 2: 11960 SW 144TH STREET CITY: MIAMI STATE: FL ZIP: 33186 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IN8BIO, INC. CENTRAL INDEX KEY: 0001740279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825462585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: EMPIRE STATE BUILDING STREET 2: 350 5TH AVENUE, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: (646) 600-6438 MAIL ADDRESS: STREET 1: EMPIRE STATE BUILDING STREET 2: 350 5TH AVENUE, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: Incysus Therapeutics, Inc. DATE OF NAME CHANGE: 20180510 4 1 form4-10082024_041004.xml X0508 4 2024-10-04 0001740279 IN8BIO, INC. INAB 0001434099 Brandt Peter C. C/O IN8BIO, INC. 350 5TH AVE. SUITE 5330 NEW YORK NY 10118 true false false false 0 Common Stock 2024-10-04 4 A 0 253164 A 517604 D Common Stock 105290 I See footnote Series A Warrants (right to buy) 1.25 2024-10-04 4 D 0 81967 D 2025-06-13 Common Stock 81967 0 D Series A Warrants (right to buy) 0.45 2024-10-04 4 A 0 81967 A 2025-10-04 Common Stock 81967 81967 D Series C Warrants (right to buy) 0.27 2024-10-04 4 A 0 253164 A 2027-10-04 Common Stock 253164 253164 D The reported securities are included within 253,164 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 253,164 shares of common stock. The securities are held by The Peter C. Brandt 2020-4 GRAT (the "GRAT"). The Reporting Person is the trustee of the GRAT and, as such, has voting and investment power over the shares held by the GRAT. The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025. Fully vested and exercisable. The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock. /s/ Jason Minio, Attorney-in-Fact 2024-10-08